Auph short interest

Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Shor

Jun 16, 2023 · In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ... The Whisper Report ® Grades Earnings Guidance Reactions Strategies Earnings Screener Short Interest ... AUPH. Aurinia Pharm Ord. $8.65. -0.52. -5.67%. Overview ...Short Squeeze - Canada; Short Squeeze - Hong Kong; Highest Cost to Borrow; Highest Short Float; Owners Retail Ownership Most Popular Funds Activist Investors Fund Sentiment - World. United States Canada UK Hong Kong Japan Australia New Zealand. Germany Switzerland Spain Poland Netherlands Greece France Ireland Italy Belgium …Web

Did you know?

Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...Biotech stocks are very interest rate sensitive and I suspect once the Federal Reserve pivots and begins cutting interest rates, AUPH and the rest of the sector's stocks will move materially ...Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ...Short interest is the volume of POINT Biopharma Global shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 4,390,000 shares of PNT short. 5.09% of POINT Biopharma Global's shares are currently sold short. Learn More on POINT Biopharma Global's current short interest.Introduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at …Thinking about investing in Aurinia Pharmaceuticals because of the upcoming earnings date annual report or stock price forecast? Check out AUPH short interest and earnings date annual report by comparing AUPH insider trading history and institutional ownership breakdown to maximise your investment return on the stock market.Short term loan lenders offer loans based on current income or assets and not one’s credit score. Because of this many people choose to get a short title loan when they’re in need of money.Sep 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ... In depth view into Aurinia Pharmaceuticals Short Interest including historical data from 2008, charts and stats. ... View Short Interest for AUPH. Upgrade now. Sep '18. Jan '19. May '19 . 285.00. 270.00. 255.00. 240.00. Historical Short Interest Data. View and export this data back to 2014.WebIn this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price.9 Des 2019 ... (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage ... short form base shelf prospectus (the “Base Shelf Prospectus”) dated ...Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has seen a decrease in hedge fund interest in recent months. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was in 24 hedge funds' portfolios at the end of ...In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...On another thread there us a guy who is misguided and blaming mgmt. Claims short interest is going up. I checked itsv8.5% as of May 15th. We should soon find out if short interest has gone up.Live Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHApproximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ...AUPH has no debt and, even better, 400 millions in cash. Good market penetration so far (100 patients Q1, 400 Q2) and guidance provided for the end of the year (40-50 millions) with great expectations for the next years (200 in 2022, 400 in 2023, sales peak at 1.5 billions) ... The short interest. Since the FDA Approval in Jan 2021, the stock ...Nov 29, 2023 · Short Interest. Percentage of Shares ShortedThe Whisper Report ® Grades Earnings Guidance Reactions Strat Interest Coverage Financials. AUPH's profit margin has increased... subscribe to Premium to read more. Profit Margin Growth Financials. ... AUPH's cash and short-term investments... subscribe to Premium to read more. Debt Coverage Financials. AUPH vs Biotech Stocks. Ticker Market Cap 1d % P/E P/B; AUPH: $1.18B +4.44%-15.53x:The 5-day price performance for the stock is 13.73%, and 26.09% over 30 days. With these gigs, the year-to-date price performance is 114.82%. Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Institutional Owners: 318 total, 304 long o Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...AUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet; This page provides short interest, short volume, short volume ratio

Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, AMEX, OTCBB and Pink Sheets stocks available from shortsqueeze.com.Live Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHApr 24, 2023 · MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ... AUPH short interest is 8.5%. Also see, Alnylam Pharma is said to be a potential target for Novartis.

In depth view into Aurinia Pharmaceuticals Short Interest including historical data from 2008, charts and stats. ... View Short Interest for AUPH. Upgrade now. Sep '18. Jan '19. May '19 . 285.00. 270.00. 255.00. 240.00. Historical Short Interest Data. View and export this data back to 2014.WebAnalyst’s Disclosure: I/we have a beneficial long position in the shares of AUPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ...Canadian biotech Aurinia Pharmaceuticals (AUPH) lost ~22% pre-market Thursday even after announcing better-than-expected financials for Q3 2022 as the company lowered its full-year...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. AUPH / Aurinia Pharmaceuticals Inc short borrow fee rates . Possible cause: Jul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the.

Short Float / Ratio: 13.17% / 8.88: Perf Quarter-4.23%: Sales: 158.85M: P/S: 8.19: EPS this Y: 31.36%: Inst Trans: 9.16%: Short Interest: 17.19M: Perf Half Y-5.03%: Book/sh: 2.73: P/B: 3.32: EPS next Y: 29.71%: ROA-14.80%: Target Price: 13.21: Perf Year: 76.61%: Cash/sh: 2.35: P/C: 3.85: EPS next 5Y-ROE-18.94%: 52W Range: 4.07 - 12.43: Perf YTD ...Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

HRTX 1.3100 (+20.18%) Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.Aug 3, 2023 · Some thoughts on AUPH: 1. As cited, AUPH reported Lupkynis sales +46% YOY, +20% over Q1, and raised full year guidance to $150 million - $160 million, but admittedly is only scratching the surface ... Sep 17, 2019 · Exhibit 99.1 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967 Short term investments (note 4) 3,975 7,889 Accounts receivable and ...

AUPH short interest is 8.5%. Also see, Alnylam Aug 15, 2022 · Analyst’s Disclosure: I/we have a beneficial long position in the shares of AUPH either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my ... As of November 15th, there was short interest totaling 2,500 shares, a decline of 56.1% from the October 31st total of 5,700 shares. Based on an average trading volume of 18,700 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company's stock are sold short. View Anebulo Pharmaceuticals' Short Interest. Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -Jan 4, 2023 · Aurinia Pharmaceuticals ( NA MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ...Aurinia Pharm Ord (AUPH) Company Description. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental …Web Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, lates Aurinia Pharm Ord (AUPH) Company Description. Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental …Web View the latest Aurinia Pharmaceuticals Inc.Aptevo Therapeutics saw a decline in short interest in November. AsAre you also wondering what is the USD to V AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on... AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on... Aurinia Pharma (AUPH) is scheduled to an Hudbay Minerals (TSE:HBM – Get Rating) (NYSE:HBM) had its price target raised by BMO Capital Markets from C$14.00 to C$15.00 in a research note released on Friday, BayStreet.CA reports. Other equities analysts also recently issued research reports about the company. National Bankshares upped their price objective on Hudbay Minerals …Web On another thread there us a guy who is misg[A high-level overview of Aurinia PharmacAUPH - Short squeeze stock short interes As a student, you need to stretch every dollar you have. The good news is there are many banks that help students grow their income by offering high interest rates on their savings.